Supernus Pharmaceuticals Inc (SUPN) Cotización

Just found this one - Well over a year since last posts...why is that ? Seems like a solid stock

I hope everyone got some 28 es because tomorrow we gap hard and run for the. Boarder get your shares at open

Wow that’s amazing news tomorrow gap up will be amazing

Boom we’re heading to 50 dollars a share tomorrow

what about the PDUFA on the 8th? will it be delayed? what do u expect the PPS if it is approved/

NEWS: $SUPN Supernus Pharmaceuticals Inc (SUPN) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Q3 2020 Earnings Call Nov 4, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: Supernus Pharmaceuticals Inc (SUPN) Q3 2020 Earnings Call Trans...

Read the whole news SUPN - Supernus Pharmaceuticals Inc (SUPN) Q3 2020 Earnings Call Transcript

SUPN will easily be over 50 dollars on Monday after PDUFA comes out this weekend, you have to been in by Friday. Good luck.

30-35 dollars easy tomorrow with this awesome earnings beat. Way undervalued on all fronts. Sitting on 5000 shares.

* * $SUPN Video Chart 11-06-19 * *

Link to Video - click here to watch the technical chart video

$SUPN on watch for bottom to drop out sub $40

https://stocknews.com/news/supn-cantor-fitzgerald-reiterates-overweight-rating-31-pt-11867294/

SUPN continues to be a big winner. Just look at the prescription growth in the last three years. With this indication now added on label, continued growth is ahead. SUPN customers require long term drug therapy. Investors can't ask for a better situation. The pipeline continues to look good, too.

Big news AH. Go SUPN

Great Conference Call and Another Big Growth Year in 2016 -- The FDA approval of the migraine indication is about to happen. This company has a solid ongoing revenue stream that will expand significantly in 2017 and likely again for the next several years. The reason is simple. SUPN has "customers for life." The nonsense in Washington has little effect as these customers require constant daily medication. SUPN's epilepsy franchise is strong with Oxtellar XR, an extended-release oxcarbazepine; and Trokendi XR, an extended-release topiramate. Epilepsy patients and their docs appreciate the minimize side effects that this mandatory medicine has. The ADHD drug pipeline holds significant potential, too. This is a very important need, too. Prescriptions for Oxtellar and Trokendi continue to grow nicely, with patent protection exclusivity until 2023. There is a long clear runway to ramp up revenues ahead for SUPN when you look at the facts...not news blubs. With a forward P/E under 16 and quarterly revenue growth of 40+%, SUPN continues to be an investment gem, despite the day traders playing with the price around quarterly report time. SUPN is going higher.

Positive SA article on SUPN:
http://seekingalpha.com/article/4034630-supernus-pharmaceuticals-offers-rare-opportunity-investors

Summary

Supernus is a biotech firm with approved products..

Sales from these products are growing at an impressive rate..

The stock is underfollowed by analyst and may still be "under the radar"..

The company offers a promising pipeline with two compounds in Phase II/Phase III clinical trials.

Introduction

Supernus Pharmaceuticals (NASDAQ:SUPN) is a rarity among the thousands of publicly-traded biotechnology firms; it has approved products, revenue and earnings. While the company's sales are growing at a double digit rate, it also has promising drug candidates working their way through late-stage clinical trials. Preliminary results from these trials have been positive, and both compounds offer substantial revenue potential if approved. With a promising pipeline, strong top and bottom line growth and only a handful of analysts covering the stock, Supernus' stock may be poised to continue its market-beating performance.

Long SUPN

No reason for SUPN to sell off. FDA approval for migraine indication is only four months away. This should add significant sales. Also, existing prescription sales continue to grow. Plus all active FDA trials continue to look good. Can't find any negatives to SUPN's fundamentals. Puzzling dip in price.

Supernus Announces Positive Results from Phase IIb Clinical Trial For SPN-812 in Children with ADHD
Now - DJNF
Supernus Announces Positive Results from Phase IIb Clinical Trial For SPN-812 in Children with ADHD
-- Study confirms efficacy and tolerability of SPN-812, a novel

non-stimulant product, in children with ADHD

-- Study meets primary endpoint with statistically significant reduction in

ADHD symptoms

-- Conference call and webcast to discuss results at 9:00 a.m. ET, October

11, 2016

ROCKVILLE, Md., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from its Phase IIb dose-ranging clinical trial of SPN-812 in children for the treatment of attention deficit hyperactivity disorder (ADHD).

The trial was successful in meeting the primary endpoint, demonstrating that SPN-812 at daily doses of 400 mg, 300 mg and 200 mg achieved a statistically significant improvement in the symptoms of ADHD from baseline to end of study as measured by the ADHD Rating Scale-IV. All SPN-812 doses tested in the trial were well tolerated. Based on these positive results in children with ADHD and the positive Phase IIa results in adults with ADHD, Supernus plans to have an end-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) after which it will initiate Phase III clinical testing.

"We are very excited about these results and that SPN-812 met the objectives of the study with an encouraging and strong clinical profile, " stated Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. "We believe SPN-812 has the potential of being a well differentiated treatment for ADHD that sets itself apart from current treatment options."

Phase IIb Study Design

The study was a randomized, double-blind, placebo controlled, multicenter, dose-ranging clinical trial in children 6 to 12 years of age diagnosed with ADHD. Each treatment was administered orally once a day over five weeks, after a three week titration phase. A total of 222 patients were randomized in the study across placebo and four doses of SPN-812 (100/200/300/400mg). The primary objective of the study was to assess the effect of SPN-812 in reducing the symptoms of ADHD in children. The primary outcome measure was the change from baseline to the end of the study in the ADHD-RS-IV total score. Safety and tolerability of SPN-812 were assessed by the monitoring of adverse events, clinical laboratory tests, vital signs, ECGs, suicidality and physical examinations. Patients who completed the study were offered the opportunity to continue into an open-label phase that is currently on-going.

Topline Results

At the end of the study, SPN-812 400 mg, 300 mg and 200 mg doses were statistically significant compared to placebo in the primary endpoint. Patients receiving SPN-812 400 mg, 300 mg and 200 mg had a -19.0 point change (p=0.021), -18.6 point change (p=0.027) and a -18.4 point change (p=0.031) from baseline, respectively, in the primary endpoint vs. -10.5 for placebo.

This primary analysis using the Intent-To-Treat (ITT) population with last observation carried forward (LOCF) was confirmed with sensitivity analyses using the Per Protocol population and Mixed Model Repeated Measures (MMRM).

With respect to the effect size, patients receiving SPN-812 400 mg, 300 mg and 200 mg had a median effect size of 0.63, 0.60 and 0.55, respectively. Patients receiving SPN-812 100 mg had a -16.7 point change from baseline in the primary endpoint and a median effect size of 0.46, which did not quite reach statistical significance (p=0.089) in this relatively low number of patients.

In addition, SPN-812 400 mg, 300 mg and 200 mg met the Clinical Global Impression Severity (CGI-S) secondary endpoint with p- values of 0.014, 0.015 and 0.031, respectively, compared to placebo.

"These results exhibit a strong clinical efficacy profile with effect sizes that are typically not seen with non-stimulants. In addition, of the 160 patients who completed the trial, 87% or 139 patients chose to enter the open-label phase showing a high level of confidence in SPN-812," stated Dr. Stefan Schwabe, Executive Vice President R&D, Chief Medical Officer of Supernus Pharmaceuticals.

SPN-812 was well tolerated in the study. All four active doses were well tolerated, with adverse events almost entirely mild or moderate in severity. Two subjects experienced three adverse events that were classified as severe and related to the medication; one on 400 mg with easy tearfulness and intermittent irritability and another on 200 mg with decreased appetite. There were no serious adverse events or deaths in the study. The most frequent adverse events across all the active doses were primarily somnolence, headache, decreased appetite, fatigue, vomiting and nausea. On average, the percentage of patients discontinuing the study due to adverse events for all active doses of SPN-812 was low at 6.7%.

"We believe this side effect profile compares very well with existing treatments in the market," added Dr. Schwabe.

Product Pipeline

SPN-812 is the company's second psychiatry product in late stage development. Supernus is also developing SPN-810 (molindone hydrochloride), a novel treatment for impulsive aggression in patients with ADHD. SPN-810 is currently in clinical development with two Phase III trials in children with ADHD.

"We are excited about our psychiatry pipeline, with two late-stage novel product candidates with positive Phase II clinical results. With SPN-812 now proceeding towards Phase III clinical testing, Supernus expects to have two product candidates in Phase III testing in 2017. We believe these two product candidates represent a significant platform for future growth for Supernus in multi-billion dollar markets," added Jack Khattar.

Really, I cant believe no one is following this on here.

Harry has posted Charts of the Day video on SUPN at TheTechTrader site noting:Supernus Pharmaceuticals, Inc. (SUPN) is one of the better junior biotech’s. The Feb low was under 10, and now it has gotten up to 20, more than doubling in that amount of time and in multiple waves. On Tuesday it was up 1.01 to 19.06, or 5.6%, on 425,492 shares traded. It may very well be headed toward the 20-21 zone, even as high as 23 short-term. It has 5.6 days to cover. http://tinyurl.com/j7gr482

Harry has posted Charts of the Day video on SUPN at TheTechTrader site noting:Supernus Pharmaceuticals, Inc. (SUPN) is one of the better junior biotech’s. The Feb low was under 10, and now it has gotten up to 20, more than doubling in that amount of time and in multiple waves. On Tuesday it was up 1.01 to 19.06, or 5.6%, on 425,492 shares traded. It may very well be headed toward the 20-21 zone, even as high as 23 short-term. It has 5.6 days to cover. http://tinyurl.com/j7gr482

Harry has posted Charts of the Day video on SUPN at TheTechTrader site noting:Supernus Pharmaceuticals, Inc. (SUPN) is one of the better junior biotech’s. The Feb low was under 10, and now it has gotten up to 20, more than doubling in that amount of time and in multiple waves. On Tuesday it was up 1.01 to 19.06, or 5.6%, on 425,492 shares traded. It may very well be headed toward the 20-21 zone, even as high as 23 short-term. It has 5.6 days to cover. http://tinyurl.com/j7gr482

Harry has posted Charts of the Day video on SUPN at TheTechTrader site noting:Supernus Pharmaceuticals, Inc. (SUPN) continues moving in a rising channel, up 44 cents to 18.85, or 2.39%, on 431,200 shares traded. It has taken out resistance and may very well test 19.25but more importantly 20-201/2. It has 4.9 days to cover.

$SUPN recent news/filings

bullish 15.65

## source: finance.yahoo.com

$SUPN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$SUPN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SUPN/company-info
Ticker: $SUPN
OTC Market Place: Not Available
CIK code: not found
Company name: Supernus Pharmaceuticals, Inc.
Incorporated In:

Business Description:

$SUPN share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$SUPN extra dd links

Company name: Supernus Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SUPN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SUPN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SUPN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/news - http://finance.yahoo.com/q/h?s=SUPN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SUPN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SUPN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SUPN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Supernus+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Supernus+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Supernus+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SUPN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SUPN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SUPN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SUPN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SUPN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SUPN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SUPN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SUPN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SUPN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SUPN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SUPN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SUPN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SUPN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SUPN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SUPN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SUPN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SUPN



$SUPN DD Notes ~ http://www.ddnotesmaker.com/SUPN

$SUPN recent news/filings

bullish optionable
crossing moving average
stochastics oversold and crossing up

## source: finance.yahoo.com

Fri, 28 Aug 2015 20:33:00 GMT ~ SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/150828/supn8-k.html
*********************************************************

Thu, 27 Aug 2015 20:44:18 GMT ~ Supernus to Attend FBR Healthcare Conference on September 9th

[at noodls] - ROCKVILLE, Md., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of ...

read full: http://www.noodls.com/view/C7DBBC34B525142F14EAE4E49F979929AA833DC5
*********************************************************

Thu, 27 Aug 2015 20:32:00 GMT ~ Supernus to Attend FBR Healthcare Conference on September 9th

[GlobeNewswire] - ROCKVILLE, Md. -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...

read full: http://finance.yahoo.com/news/supernus-attend-fbr-healthcare-conference-203200972.html
*********************************************************

Thu, 20 Aug 2015 17:04:16 GMT ~ SUPERNUS PHARMACEUTICALS INC Financials


read full: http://finance.yahoo.com/q/is?s=supn
*********************************************************

Fri, 07 Aug 2015 11:07:24 GMT ~ SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/150807/supn10-q.html
*********************************************************

$SUPN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$SUPN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SUPN/company-info
Ticker: $SUPN
OTC Market Place: Not Available
CIK code: not found
Company name: Supernus Pharmaceuticals, Inc.
Incorporated In:

Business Description:

$SUPN share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$SUPN extra dd links

Company name: Supernus Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SUPN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SUPN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SUPN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/news - http://finance.yahoo.com/q/h?s=SUPN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SUPN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SUPN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SUPN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Supernus+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Supernus+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Supernus+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SUPN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SUPN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SUPN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SUPN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SUPN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SUPN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SUPN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SUPN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SUPN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SUPN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SUPN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SUPN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SUPN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SUPN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SUPN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SUPN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SUPN



$SUPN DD Notes ~ http://www.ddnotesmaker.com/SUPN

SUPN W

SUPN W

Inst % Owned = 86%

EPS = .47

SUPN 30 D W

$SUPN recent news/filings

bullish

## source: finance.yahoo.com

Thu, 21 May 2015 20:31:25 GMT ~ SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, F


read full: http://biz.yahoo.com/e/150521/supn8-k.html
*********************************************************

Tue, 19 May 2015 21:16:20 GMT ~ Supernus to Present at June Jefferies Healthcare Conference

[at noodls] - ROCKVILLE, Md., May 19, 2015 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of ...

read full: http://www.noodls.com/view/280BE4BC15A9CD7D80DEF942035FF411925E0757
*********************************************************

Tue, 19 May 2015 20:30:00 GMT ~ Supernus to Present at June Jefferies Healthcare Conference

[GlobeNewswire] - ROCKVILLE, Md. -- Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced ...

read full: http://finance.yahoo.com/news/supernus-present-june-jefferies-healthcare-203000705.html
*********************************************************

Fri, 15 May 2015 17:04:25 GMT ~ SUPERNUS PHARMACEUTICALS INC Financials


read full: http://finance.yahoo.com/q/is?s=supn
*********************************************************

Wed, 06 May 2015 21:33:56 GMT ~ SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/150506/supn10-q.html
*********************************************************

$SUPN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$SUPN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SUPN/company-info
Ticker: $SUPN
OTC Market Place: Not Available
CIK code: not found
Company name: Supernus Pharmaceuticals, Inc.
Incorporated In:

Business Description:

$SUPN share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$SUPN extra dd links

Company name: Supernus Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SUPN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SUPN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SUPN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/news - http://finance.yahoo.com/q/h?s=SUPN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SUPN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SUPN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SUPN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Supernus+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Supernus+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Supernus+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SUPN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SUPN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SUPN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SUPN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SUPN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SUPN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SUPN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SUPN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SUPN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SUPN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SUPN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SUPN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SUPN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SUPN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SUPN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SUPN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SUPN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SUPN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SUPN



$SUPN DD Notes ~ http://www.ddnotesmaker.com/SUPN

How am I the only one following this stock on IHUB?

Good earnings report:

http://seekingalpha.com/pr/12786626-supernus-announces-fourth-quarter-and-full-year-2014-results

decent earnings

very confused as to why this is down...anyone have any ideas on it..
Seems to me everything is going the right direction except share price...

They are hiring. I have a head hunter all over me.
Should I stay in my manage care management sales position with Gilead or give these guys any consideration?

Anti seizure drug? I thought the Medical Mary Jane sector had wrapped up with Charlotte's web and Carly's Law. Alabama of all States vote on that tomorrow. The Governor has stated he will sign it into law if it makes it to his desk tomorrow. And he's a frigg'n Doctor! Compete with that.

Gilead has an arterial hypertension drug that is in an over saturated market.
Small pharma is fun to cut your teeth in on, but looking to pass.

Lower highs and lower lows. I might make a flip play on the next dip.

yesterdays gains could have been a small short squeeze right before earnings. though earnings haven't been great the last 2Qs, there has always been a positiv stock reaction after they have been announced lately. looking foward to fill the gap @$9.81 but very little shares have been traded between $8.80 - $11.40. i think some volume could cause a heavy spike upwards to that number but just imo.

9:05AM Supernus Pharma announces issuance of third US patent protecting oxtellar XR (SUPN) 8.11 : Co announced the issuance of a third patent (number 8,617,600) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, its novel once-daily extended-release oxcarbazepine product.

The patent was issued by the USPTO on December 31, 2013. It provides protection for the product with expiration that is no earlier than 2027. Supernus has several additional patent applications for extended-release topiramate and extended-release oxcarbazepine pending in other geographic regions

first weekly close above $8 since nov. 2012. big short position here. could get interesting in the coming weeks.

I just wanted post #100.

8-k Item 5.02 Departure of Directors and Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of Director

On December 23, 2013, Michael Bigham tendered his resignation from the board of directors of Supernus Pharmaceuticals, Inc. (the “Company”), effective immediately. Mr. Bigham was the designee of Abingworth Bioventures IV LP and its affiliates (“Abingworth”), an original investor in the Company. His resignation was consistent with Abingworth’s general practice of limiting the time its representatives spend on a portfolio company’s board of directors after it becomes a public company. The Company is presently searching for a replacement to fill the remainder of Mr. Bigham’s term, which expires at the next annual meeting of stockholders in 2014. A copy of the press release regarding the resignation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Mr. Bigham was a member of the Company’s Compensation Committee and Governance and Nominating Committee. John M. Siebert, Ph.D. will fill the vacancy on the Company’s Compensation Committee and M. James Barrett, Ph.D. will fill the vacancy on the Company’s Governance and Nominating Committee.

Item 8.01 Other Events.

On December 23, 2013, Supernus issued a press release announcing that the Food and Drug Administration approved Orenitram™ (treprostinil), Extended Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity. Supernus developed the extended release formulation of Orenitram™ under a Development and License Agreement with United Therapeutics Corporation (NASDAQ: UTHR). The product uses EnSoTrol, Supernus’ novel osmotic technology platform. A copy of the press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following document is furnished as an Exhibit pursuant to Item 5.02 hereof:

Exhibit 99.1 — Press Release Dated December 24, 2013 of the Company providing details regarding the resignation of Michael Bigham from the Company’s board of directors.

Exhibit 99.2 — Press Release Dated December 23, 2013.

Yup...not sure that moved the stock, in and of itself. They explained it.

See where a board member resigned this morning??? Rooofl!

Yup...just as always...this stock is a POS for a LT hold...I really do not know why. Glad I dumped yesterday. Guess I will reload at some future point, when the PPS falls more.

Yup...did the same think it did last time...up in pre-mkt and downward drift...I sold my 50 calls for a bit less than $4,500 profit. You know, this appears to be a workable strategy. Wait for the downward drift, and load up on slightly below or at-the-money calls about 6 months out, wait for good news, and sell. This was nearly a double and I only had to hold since late October.

$8.73 Pre-Market

Thanks! I did not consider the short position. Missing both top and bottom lines was not good. Generally, the PPS has been crappy ever since the secondary at $8 PPS. Maybe I will have a bit of good luck. I was bracing myself for tax loss selling on this one, which is why I only nibbled some of the June 2014 calls.

i would consider ~40% of float short, an outlook about burning less cash than expected and to be break even by end of 2014 good fuel to light this puppy.

I bought 50 $7 strike calls for June 21, 2014, and thought I would get clobbered, today, but the PPS is going up and I am happy...I just don't know why the PPS is going up.

what i really like about their guidance despite their growing sales is that SUPN announced that they are expecting to burn lower cash for the full year 2013 ($70-75M) as previously anticipated ($85-95M).

during the nine month till 09/30 they already burned $69.9M and nonetheless they are narrowing their forecasts... is there something to happen in Q4?

volume is impressive today with two trades over 1 million shares each. price lags so far. curious where it will close today.